Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;306(3):639-662.
doi: 10.1007/s00404-021-06361-8. Epub 2022 Jan 27.

Prognostic utility of the ovarian cancer secretome: a systematic investigation

Pradnya R Kamble #  1 , Ananya A Breed  1 , Apoorva Pawar #  1 , Grishma Kasle  1   2 , Bhakti R Pathak  3
Affiliations
Review

Prognostic utility of the ovarian cancer secretome: a systematic investigation

Pradnya R Kamble et al. Arch Gynecol Obstet. 2022 Sep.

Abstract

Background: Ovarian cancer is usually detected at an advanced stage with frequent recurrence. The recurrence-free survival and overall survival is influenced by the age at diagnosis, tumor stage and histological subtype. Nonetheless, quantifiable prognostic biomarkers are needed for early identification of the high-risk patients and for personalized medicine. Several studies link tumor-specific dysregulated expression of certain proteins with ovarian cancer prognosis. However, careful investigation of presence of these prognostically relevant proteins in ovarian cancer secretome is lacking.

Objective: To critically analyze the recent published data on prognostically relevant proteins for ovarian cancer and to carefully search how many of them are reported in the published ovarian cancer secretome datasets.

Design: A search for relevant studies in the past 2 years was conducted in PubMed and a comprehensive list of proteins associated with the ovarian cancer prognosis was prepared. These were cross-referred to the published ovarian cancer secretome profiles. The proteins identified in the secretome were further shortlisted based on a scoring strategy employing stringent criteria.

Results: A panel of seven promising secretory biomarkers associated with ovarian cancer prognosis is proposed.

Conclusion: Scanning the ovarian cancer secretome datasets provides the opportunity to identify if tumor-specific biomarkers could be tested as secretory biomarkers. Detecting their levels in the body fluid would be more advantageous than evaluating the expression in the tissue, since it could be monitored multiple times over the course of the disease to have a better judgment of the prognosis and response to therapy.

Keywords: Biomarker; Ovarian cancer; Prognosis; Secretome.

PubMed Disclaimer

References

    1. Hoppenot C, Eckert MA, Tienda SM, Lengyel E (2018) Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol 148:204–212. https://doi.org/10.1016/j.ygyno.2017.10.032 - DOI - PubMed
    1. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG (2008) Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 44:946–953. https://doi.org/10.1016/j.ejca.2008.03.006 - DOI - PubMed
    1. Gadducci A, Cosio S (2009) Surveillance of patients after initial treatment of ovarian cancer. Crit Rev Oncol Hematol 71:43–52. https://doi.org/10.1016/j.critrevonc.2008.12.008 - DOI - PubMed
    1. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S et al (2007) CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients: from The Danish “MALOVA” Ovarian Cancer Study. Gynecol Oncol 104:508–515. https://doi.org/10.1016/j.ygyno.2006.09.028 - DOI - PubMed
    1. Szajnik M, Czystowska-Kuźmicz M, Elishaev E, Whiteside TL (2016) Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Rev Mol Diagn 16:811–826. https://doi.org/10.1080/14737159.2016.1194758 - DOI - PubMed - PMC

Publication types

LinkOut - more resources